Evaluating the Long-term Safety and Tolerability of Imatinib in Patients with Lymphangioleiomyomatosis (LAM)

Phase

Condition

Lymphangioleiomyomatosis

Treatment

Placebo

Imatimib Mesylate

Clinical Study ID

NCT06889168

AAAT1955

Ages 18-64
Female

Study Summary

Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and effective medications. A large National Institute of Health study called MILES showed that sirolimus (also known as Rapamycin) improved lung function in individuals with LAM. Since most individuals with LAM and impaired lung function are now on sirolimus, future studies may prove more difficult. Laboratory studies suggested that Imatinib mesylate (imatinib), an FDA-approved drug for leukemia, initiates LAM cell death. A pilot trial with imatinib titled "Imatinib Mesylate for the treatment of Lymphangioleiomyomatosis" - (LAMP-1) was funded by the Department of Defense in 2016, and documented (1) the safety of use of tyrosine kinase inhibitors in patients with LAM; (2) the safety of concurrent use of tyrosine kinase and mTOR inhibitors; and, (3) short term variability in vascular endothelial growth factor D (VEGF-D) - a LAM biomarker, as a response to therapies. Due to the short-term LAMP-1 trial, LAMP-2 will be a longer-term 6-month clinical study evaluating the safety and tolerability of imatinib in patients with LAM. Patients that participate in the trial will come in for 5 office visits and check-up phone calls every 2 weeks over the course of 6 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Women 18 through 64 years of age (inclusive)
Pulmonary Function Test (PFT) with following criteria:

DLCO >20% predicted and FVC <90% OR
Post bronchodilator FEV1 between 30% and 90% predicted.

Confirmed or possible diagnosis of LAM
Willing to avoid grapefruit juice and St. John's wort while in the study
Able and willing to comply with the study procedures

Exclusion

Exclusion Criteria:

Women who have or will undergo a transplant
Women who will undergo surgery
Women who are currently pregnant or plan on a pregnancy
Women who are currently breast feeding or lactating
Dementia or other cognitive dysfunction that, in the opinion of the investigator,would prevent the participant from consenting to the study or completing studyprocedures
Currently taking any of the following medications:
Antifungal Medications: Ketoconazole; Itraconazole ; Voriconazole.
Antibiotics for bacterial infections: Clarithromycin.
Analgesics to treat headaches/migraines: Dihydroergotamine; Dihydroergotamineintranasal
Antiretroviral protease inhibitors used in human immunodeficiency virus (HIV)infections: Atazanavir ; Nelfinavir; Indinavir; Ritonavir; Saquinavir
Anti-epileptic or seizure medications: Carbamazepine, Fosphenytoin;Oxcarbamazepine; Phenobarbital ; Phenytoin; Primidone
Anti-depressant medications: Nefazodone; St. John's wort
Targeted cancer drugs: Regorafenib; Venetoclax ; Cobimetinib
Ivabradine (used to treat chronic heart failure); Telithromycin (used to treatcommunity acquired pneumonia); Lomitapide (treatment of familialhypercholesterolemia); Lonafarnib (Hutchinson-Gilford progeria syndrome);conivaptan (treat low sodium levels); flibanserin (management of hypoactivesexual desire disorder (HSDD)); Naloxegol (opioid-induced constipation);Warfarin (prevent blood clots); Lurasidone (schizophrenia and bipolardepression); Eliglustat (treatment of Gaucher's disease).
Non English speaking, illiterate, or other vulnerable persons will not be includedamong study subjects.
Any condition that in the opinion of the investigator might adversely influence thestudy outcome.

Study Design

Placebo

April 01, 2025

August 31, 2026

Study Description

Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that is due to a very slow growing cancer that proliferates via unopposed activity of the mTOR pathway. A large NIH study (MILES) found that sirolimus (Rapamycin) that inhibits the mTOR pathway improved lung function and quality of life compared to placebo in LAM. Sirolimus has been shown to cause growth suppression but not apoptosis of LAM cells in culture. Additionally, not all patients with LAM have a clinical effect with sirolimus. Recently, imatinib mesylate has been shown to induce LAM cell apoptosis, raising the possibility of more lasting therapy for LAM. Currently, most LAM patients are on sirolimus and attempts to find sirolimus naive patients have not been successful for other studies. LAM cells use the mesenchymal PDGF receptor pathway for proliferation, similar to certain leukemias and slow growing neoplasms. Laboratory studies suggested that Imatinib mesylate (imatinib), an FDA approved drug for leukemia, initiates LAM cell death. A pilot trial with imatinib (LAMP-1) was funded by the DOD in 2016, and documented (1) the safety of use of tyrosine kinase inhibitors in patients with LAM; (2) the safety of concurrent use of tyrosine kinase and mTOR inhibitors; and, (3) short term variability in VEGF-D as a response to therapies. Concurrent cell-based research studies during this time showed equally efficacious tumoricidal activity of nilotinib in vitro. Due to the short-term LAMP-1 trial, the investigators propose a longer-term clinical study evaluating the safety and tolerability of imatinib in patients with LAM.

Connect with a study center

Columbia University Irving Medical Center
New York, New York 10032
United States
Active - Recruiting
Medical University of South Carolina
Charleston, South Carolina 29425
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.